Detalhe da pesquisa
1.
Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer.
N Engl J Med
; 389(16): 1453-1465, 2023 Oct 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-37851874
2.
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial.
Lancet
; 403(10421): 31-43, 2024 Jan 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38048793
3.
Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study.
Lancet Oncol
; 25(1): 29-45, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38101433
4.
Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study.
Lancet Oncol
; 25(1): 46-61, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38101431
5.
Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial.
Lancet
; 402(10398): 291-303, 2023 07 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-37285865
6.
Development of a Prognostic Model for Early Breast Cancer Integrating Neutrophil to Lymphocyte Ratio and Clinical-Pathological Characteristics.
Oncologist
; 29(4): e447-e454, 2024 Apr 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37971409
7.
CDK4/6-Inhibitors Versus Chemotherapy in Advanced HR+/HER2-Negative Breast Cancer: Results and Correlative Biomarker Analyses of the KENDO Randomized Phase II Trial.
Oncologist
; 29(5): e622-e634, 2024 May 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38175669
8.
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.
N Engl J Med
; 384(14): 1289-1300, 2021 04 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33616314
9.
Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study.
Cancer Immunol Immunother
; 73(6): 106, 2024 Apr 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38634928
10.
Treatment of bone metastases from solid tumors with bone-modifying agents: a web survey of Italian oncologists investigating patterns of practice drug prescription and prevention of side effects.
Support Care Cancer
; 32(3): 202, 2024 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38427111
11.
Pregnancy After Breast Cancer in Young BRCA Carriers: An International Hospital-Based Cohort Study.
JAMA
; 331(1): 49-59, 2024 01 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38059899
12.
Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study.
Lancet Oncol
; 24(3): 228-238, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36858721
13.
Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial.
Lancet Oncol
; 24(3): 286-296, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37052965
14.
AMEERA-4: a randomized, preoperative window-of-opportunity study of amcenestrant versus letrozole in early breast cancer.
Breast Cancer Res
; 25(1): 141, 2023 11 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37950338
15.
A correlative biomarker study and integrative prognostic model in chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide.
Prostate
; 83(4): 376-384, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-36564933
16.
Immunogenomic profiles associated with response to life-prolonging agents in prostate cancer.
Br J Cancer
; 129(7): 1050-1060, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37443349
17.
Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer.
N Engl J Med
; 382(23): 2197-2206, 2020 06 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32469184
18.
Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study.
Cancer Immunol Immunother
; 72(9): 2961-2970, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37248424
19.
Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study.
Cancer Immunol Immunother
; 72(11): 3665-3682, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37676282
20.
Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer.
J Transl Med
; 21(1): 75, 2023 02 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36737752